Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  The Lancet Oncology

• Publication date

  2004-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(04)01508-6PMID 15231247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation

  2004cited by this paper
• A common staging system for hepatocellular carcinoma

  2004cited by this paper
• Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence‐free survival

  2003cited by this paper
• Meta‐analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma

  2003cited by this paper
• Relevance network between chemosensitivity and transcriptome in human hepatoma cells.

  2003cited by this paper
• Non‐Resective Ablation and Liver Transplantation in Patients with Cirrhosis and Hepatocellular Carcinoma (HCC): Safety and Efficacy

  2003cited by this paper
• Hepatocellular carcinoma

  2003cited by this paper
• Evolution of liver transplantation for hepatocellular carcinoma.

  2003cited by this paper
• Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome

  2003cited by this paper
• Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma

  2003cited by this paper
• Small‐for‐size syndrome: What is the problem?

  2003cited by this paper
• Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

  2003cited by this paper
• Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence‐based decision

  2003cited by this paper
• Living-donor liver transplantation for hepatocellular carcinoma

  2003cited by this paper
• Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer

  2002cited by this paper
• Prognostic prediction and treatment strategy in hepatocellular carcinoma

  2002cited by this paper
• Liver transplantation in association with hepatocellular carcinoma: An update of the international tumor registry

  2002cited by this paper
• Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria

  2002cited by this paper
• Hepatocellular carcinoma: A prime indication for living donor liver transplantation

  2002cited by this paper
• Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention‐to‐treat principle and dropout from the waiting list

  2002cited by this paper
• A randomized placebo‐controlled study of long‐acting octreotide for the treatment of advanced hepatocellular carcinoma

  2002cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Apoptosis A Link between Cancer Genetics and Chemotherapy

  2002cited by this paper
• Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon‐alpha, doxorubicin and 5‐fluorouracil chemotherapy

  2002cited by this paper
• Current results of living-related liver transplantation (LRLT) in Europe. Report from the European Liver Transplantation Registry (ELTR)

  2002cited by this paper
• [Domino or sequential liver transplantation. Is it a feasible technique?].

  2002cited by this paper
• A novel protein overexpressed in hepatoma accelerates export of NF-kappa B from the nucleus and inhibits p53-dependent apoptosis.

  2002cited by this paper
• Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.

  2002cited by this paper
• El trasplante hepático dominó o secuencial, ¿es una técnica factible?

  2002cited by this paper
• Systemic Treatment of Hepatocellular Carcinoma

  2002cited by this paper
• Analysis of tumor characteristics and survival in liver transplant recipients with incidentally diagnosed hepatocellular carcinoma

  2001cited by this paper
• Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

  2001cited by this paper
• MELD and PELD: Application of survival models to liver allocation

  2001cited by this paper
• Living donor liver transplantation for early hepatocellular carcinoma: A life‐expectancy and cost‐effectiveness perspective

  2001cited by this paper
• LIVING-DONOR VERSUS CADAVERIC LIVER TRANSPLANTATION FOR NON-RESECTABLE SMALL HEPATOCELLULAR CARCINOMA AND COMPENSATED CIRRHOSIS: A DECISION ANALYSIS1

  2001cited by this paper
• Improved survival with oral administration of enteric‐coated tegafur/uracil for advanced stage IV‐A hepatocellular carcinoma

  2001cited by this paper
• Systemic Chemotherapy with Epirubicin for Treatment of Advanced or Multifocal Hepatocellular Carcinoma

  2001cited by this paper
• Mechanisms of resistance to cisplatin.

  2001cited by this paper
• Sequential liver transplantation: 27 cases in 25 patients.

  2001cited by this paper
• Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors

  2001cited by this paper
• Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy

  2000cited by this paper
• Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

  2000cited by this paper
• Needle‐tract implantation from hepatocellular cancer: Is needle biopsy of the liver always necessary?

  2000cited by this paper
• Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?

  2000cited by this paper
• Living donor liver transplantation in adults: Outcome in Japan

  2000cited by this paper
• Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome‐oriented decision analysis

  2000cited by this paper
• Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy

  1999cited by this paper
• Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy.

  1999cited by this paper
• Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation

  1999cited by this paper
• Regulatory peptide receptors in human hepatocellular carcinomas

  1999cited by this paper
• Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.

  1999cited by this paper
• Multimodal treatment for hepatocellular carcinoma on cirrhosis: the role of chemoembolization and alcoholization before liver transplantation

  1998cited by this paper
• Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit?

  1998cited by this paper
• Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial

  1998cited by this paper
• Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

  1998cited by this paper
• Effect of preoperative radiological treatment of hepatocellular carcinoma before liver transplantation: A retrospective study

  1998cited by this paper
• Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta‐analysis?

  1998cited by this paper
• Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme)

  1998cited by this paper
• Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial.

  1998cited by this paper
• Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.

  1998cited by this paper
• Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials.

  1997cited by this paper
• Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study.

  1997cited by this paper
• Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates.

  1997cited by this paper
• Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

  1996cited by this paper
• Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

  1996cited by this paper
• Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients.

  1995cited by this paper
• Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: the experience of the National Cancer Institute of Milan.

  1993cited by this paper
• Genetic Changes and Histopathological Grades in Human Hepatocellular Carcinomas

  1993cited by this paper
• Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy

  1992cited by this paper
• Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters.

  1992cited by this paper
• Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors.

  1992cited by this paper
• Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

  1988cited by this paper
• Clinical trials in primary hepatocellular carcinoma: current status and future directions.

  1988cited by this paper
• Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma.

  1987cited by this paper
• 4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma.

  1985cited by this paper
• Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study.

  1985cited by this paper
• Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients

  1985cited by this paper
• Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.

  1984cited by this paper
• Phase II trial of mitoxantrone in patients with primary liver cancer.

  1984cited by this paper
• Primary liver cancer. An eastern cooperative oncology group trial

  1984cited by this paper
• Further experience in treating patients with hepatocellular carcinoma in Uganda

  1980cited by this paper
• Chemotherapy studies in primary liver cancer. A prospective randomized clinical trial

  1978cited by this paper
• Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication

  1975cited by this paper
• Hepatocellular Carcinoma (hcc) Causes Death in Patients with Cirrhosis and Is One of the Most Prevalent Malignant Tumours Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. a Randomized Controlled Trial

  year unknowncited by this paper

• Potential therapeutic role of Cannabidiol and vitamin D in Hepatocellular carcinoma: evidence from in vitro studies

  2026cites this paper
• Idarubicin versus Epirubicin in Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: An Open-label, Randomized, Phase IV Trial.

  2025cites this paper
• Anthracycline selection in drug-eluting-beads-transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma: emerging evidence for idarubicin

  2025cites this paper
• Seedless black Vitis vinifera polyphenols suppress hepatocellular carcinoma in vitro and in vivo by targeting apoptosis, cancer stem cells, and proliferation.

  2024cites this paper
• A history of the treatment of primary liver cancer.

  2024cites this paper
• BALAD score predicts the recurrence and survival in the patients who underwent initial hepatectomy for HCC.

  2024cites this paper
• Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials

  2023cites this paper
• A drug co-delivery platform made of magnesium-based micromotors enhances combination therapy for hepatoma carcinoma cells.

  2023cites this paper
• Chemoembolization with Degradable Starch Microspheres (DSM-TACE): expanding indications in HCC multidisciplinary tumor board

  2023cites this paper
• Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer

  2022cites this paper
• An overview of the irreversible electroporation for the treatment of liver metastases: When to use it

  2022cites this paper
• Evaluate the toxicity of silver nanoparticles by chemical and green synthesis methods

  2022cites this paper
• Cell membrane breakage and triggering T cell infiltration are involved in human telomerase reverse transcriptase (hTERT) promoter-driven novel peptide KK-64 for liver cancer gene therapy

  2021cites this paper
• Liver cancer

  2021cites this paper
• Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC

  2021cites this paper
• Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials

  2021cites this paper
• Combination of natural killer cell-based immunotherapy and irreversible electroporation for the treatment of hepatocellular carcinoma

  2021cites this paper
• Green formulation of Ag nanoparticles by Hibiscus rosa-sinensis: Introducing a navel chemotherapeutic drug for the treatment of liver cancer

  2021cites this paper
• Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization

  2020cites this paper
• Sustained release of arsenic trioxide benefits interventional therapy on rabbit VX2 liver tumor.

  2020cites this paper
• Long Non-Coding RNAs in Hepatocellular Carcinoma: Ordering of the Complicated lncRNA Regulatory Network and Novel Strategies for HCC Clinical Diagnosis and Treatment.

  2020cites this paper
• Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease

  2020cites this paper
• Synergistic co-delivery of diacid metabolite of norcantharidin and ABT-737 based on folate-modified lipid bilayer-coated mesoporous silica nanoparticle against hepatic carcinoma

  2020cites this paper
• The oncolytic efficacy and safety of avian reovirus and its dynamic distribution in infected mice

  2019cites this paper
• Hepatocellular Carcinoma: Treatment

  2019cites this paper
• The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma

  2018cites this paper
• Selective Toxicity of Non Polar Bioactive Compounds of Sea Cucumber (Holothuria sabra) extracts on Isolated Mitochondria and Hepatocytes of Induced Hepatocellular Carcinoma Rat Model

  2018cites this paper
• An Overview of Hepatocellular Carcinoma Gillian International Journal of Hepatology & Gastroenterology

  2018cites this paper
• Oncotherapies for HCC

  2018cites this paper
• Cabazitaxel, a novel chemotherapeutic alternative for drug-resistant hepatocellular carcinoma.

  2018cites this paper
• Irreversible electroporation in primary and metastatic hepatic malignancies

  2017cites this paper
• Function of myeloid cell leukaemia-1 and its regulative relations with hepatocellular carcinoma

  2017cites this paper
• Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma.

  2017cites this paper
• Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation.

  2017cites this paper
• PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma

  2017cites this paper
• Cinnamic Acid Derivatives Enhance the Efficacy of Transarterial Embolization in a Rat Model of Hepatocellular Carcinoma

  2017cites this paper
• Selective Toxicity of Persian Gulf Sea Squirt ( Phallusia nigra ) Extract on Isolated Mitochondria Obtained from Liver Hepatocytes of Hepatocellular Carcinoma Induced Rat

  2017cites this paper
• Propolis induce cytotoxicity on cancerous hepatocytes isolated from rat model of hepatocellular carcinoma: Involvement of ROS-mediated mitochondrial targeting

  2016cites this paper
• Radiation Therapy and Palliative Care Prolongs the Survival of Hepatocellular Carcinoma Patients with Bone Metastases.

  2016cites this paper
• Predictive factors of pathological vascular invasion in hepatocellular carcinoma within 3 cm and three nodules without radiological vascular invasion

  2016cites this paper
• Mechanisms of doxorubicin resistance in hepatocellular carcinoma.

  2016cites this paper
• Selective Toxicity of Apigenin on Cancerous Hepatocytes by Directly Targeting their Mitochondria.

  2016cites this paper
• The Role of FOXO3 in Mechanisms of Doxorubicin Resistance in Hepatocellular Carcinoma

  2016cites this paper
• PHARMACOLOGICAL AND TOXICOLOGICAL EVALUATION OF LOPERAMIDE & NIACIN COMBINATION EITHER CANCER PROMOTER OR INHIBITOR IN DENA INDUCED LIVER CANCER USING WISTAR RATS

  2015cites this paper
• Title Interferon-gamma Inducible Protein 10 up-regulated by acute-phase graft injury induced late-phase cisplatin resistance after liver transplantation

  2015cites this paper
• Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions

  2015cites this paper
• A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation

  2015cites this paper
• The influence of cisplatin, doxorubicin, pegylated doxorubicin, oxaliplatin and gemcitabine on mahlavu cell line.

  2015cites this paper
• A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation

  2015cites this paper
• Selective Toxicity of Persian Gulf Sea Cucumber (Holothuria parva) and Sponge (Haliclona oculata) Methanolic Extracts on Liver Mitochondria Isolated from an Animal Model of Hepatocellular Carcinoma

  2015cites this paper
• A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation

  2015cites this paper
• Interferon-gamma inducible protein 10 (IP10) induced cisplatin resistance of HCC after liver transplantation through ER stress signaling pathway

  2015cites this paper
• Gα12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4α inactivation, which causes c-Met induction

  2015cites this paper
• Treatment of Liver Cancer.

  2015influential citation
• Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma

  2015cites this paper
• Fixed dose combination therapy loperamide and niacin ameliorates diethylnitrosamine-induced liver carcinogenesis in albino Wistar rats

  2015cites this paper
• Glutathione S-transferase O2 gene rs157077 polymorphism predicts response to transarterial chemoembolization in hepatocellular carcinoma

  2015cites this paper
• Effects of fucoidan on proliferation, AMP-activated protein kinase, and downstream metabolism- and cell cycle-associated molecules in poorly differentiated human hepatoma HLF cells.

  2015cites this paper
• Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma: a systematic review and a meta-analysis.

  2015cites this paper
• Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review.

  2014cites this paper
• Metronomic Chemotherapy : Possible Clinical Application in Advanced Hepatocellular Carcinoma 1

  2014cites this paper
• Idarubicin‐loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial

  2014cites this paper
• Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma

  2014cites this paper
• Percutaneous Cryoablation for Liver Cancer

  2014influential citation
• Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.

  2014cites this paper
• Transarterial chemoembolization and bland embolization for hepatocellular carcinoma.

  2014cites this paper
• Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.

  2014cites this paper
• Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis.

  2014cites this paper
• Active hexose correlated compound potentiates the antitumor effects of low-dose 5-fluorouracil through modulation of immune function in hepatoma 22 tumor-bearing mice

  2014cites this paper
• Lipiodol Trans-arterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin: First Experience

  2013cites this paper
• Percutaneous comprehensive cryoablation for metastatic hepatocellular cancer.

  2013cites this paper
• Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1.

  2013cites this paper
• Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.

  2013cites this paper
• Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma

  2013cites this paper
• Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma.

  2013cites this paper
• Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients

  2013cites this paper
• Transarterial therapies for hepatocellular carcinoma.

  2013cites this paper
• Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.

  2013cites this paper
• Association of multiple drug resistance-1 gene polymorphism with multiple drug resistance in breast cancer patients from an ethnic Saudi Arabian population.

  2013cites this paper
• Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer.

  2013cites this paper
• Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma.

  2013cites this paper
• Hepatic Tumors: An Oncologist's Perspective

  2013cites this paper
• A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma

  2013cites this paper
• Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts

  2012cites this paper
• Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?

  2012cites this paper
• Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.

  2012cites this paper
• Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials.

  2012cites this paper
• Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma.

  2012cites this paper
• The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells.

  2012cites this paper
• Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma

  2012cites this paper
• Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib

  2011cites this paper
• Locoregional therapy for hepatocellular carcinoma.

  2011cites this paper
• Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.

  2011cites this paper
• A mechanism of apigenin-induced apoptosis is potentially related to anti-angiogenesis and anti-migration in human hepatocellular carcinoma cells.

  2011cites this paper
• Role of stress‐induced NKG2D ligands in liver diseases

  2011cites this paper
• Management of Patients with Hepatocellular Carcinoma and Extrahepatic Metastasis

  2011cites this paper
• 2 An Evidence-based Perspective of Arsenic Trioxide ( As 2 O 3 ) for Cancer Patients

  2011cites this paper
• Hepatocellular carcinoma with extrahepatic metastasis

  2011cites this paper
• An Evidence-based Perspective of Arsenic Trioxide (As2O3) for Cancer Patients

  2011cites this paper
• Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma

  2011cites this paper